₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?
Over the last 22 trading sessions, Suven Life Sciences has surged from ₹ 120 to ₹ 238 apiece, marking a sharp rise of 98.3%. The stock ended May with an impressive 92% monthly gain — its best performance since December 2020, when it had rallied 95%.
Several factors have contributed to this sharp uptrend, with one of the key drivers being the company's recently raised ₹ 857 crore through a preferential issue. In mid-May, the company's board approved the issue of 6.4 crore fully convertible warrants on a preferential basis to promoters and non-promoter entities, each priced at ₹ 134.
The funds raised will support various initiatives, including ongoing R&D efforts, clinical trials, general corporate purposes, and the development of a new research facility focused on CNS (central nervous system) therapies.
Additionally, investor sentiment remains positive due to the company's strong clinical pipeline. Suven Life Sciences is currently advancing multiple CNS-focused drug candidates through various stages of clinical trials—Phases 1, 2, and 3—for conditions such as Alzheimer's disease, narcolepsy, major depressive disorder, and cognitive impairment.
Despite the company's posting widening losses in the March quarter, investors remain optimistic about the company's long-term growth prospects. The company's emphasis on developing novel therapeutics for neurodegenerative disorders and CNS diseases, backed by the new fundraising, reinforces its potential for long-term growth, attracting investor interest.
For the March-ending quarter, the company reported a widening of consolidated net loss to ₹ 43.95 crore from ₹ 27 crore in Q4FY24, hit by a dip in revenue and higher expenses. Its consolidated revenue from operations in the quarter under review stood at ₹ 1.47 crore against ₹ 2.39 crore in the year-ago period, it added.
Total expenses in the March quarter were higher at ₹ 46.63 crore as compared to ₹ 34.21 crore in the same period a year ago. In fiscal year 2024-25, consolidated net loss widened to ₹ 160.75 crore from ₹ 105.08 crore in the previous fiscal year, while the consolidated revenue from operations in FY25 stood at ₹ 6.66 crore as compared to ₹ 11.69 crore in FY24, the company said.
The company, in its earnings filing, said that it continues the R&D programs focused on central nervous system (CNS) disease disorders and granted 20 patents during the period covering the countries of Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa, and the USA.
Suven, a biopharmaceutical company, is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs globally.
The company has a portfolio of advanced-stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), schizophrenia, pain disorders, and gastrointestinal disorders.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Toothpaste & balms can affect brain health: Doctors
1 2 3 4 Nagpur: In a shocking link between everyday hygiene products and neurological health, doctors and neuroscientists raised fresh concerns about ingredients commonly found in toothpaste, balms, and essential oil-based products that may silently impact the brain over time. Observations made during World Brain Week prompted researchers to highlight the potential neurotoxic effects of substances such as camphor, menthol, and eucalyptus — common components found in daily-use products. Experts suggest checking labels and avoiding the overuse of strong aromatic products. "Many of these ingredients can cross the blood–brain barrier via the buccal mucosa, bypassing liver metabolism," said Dr Thomas Mathew, vice dean at St John's Medical College, Bengaluru. "Repeated exposure, especially every 24 to 48 hours, can lead to a phenomenon called chemical kindling, where brain neurons become hyperexcitable, possibly triggering seizures, migraines, or other neuropsychiatric disorders," Mathew said. Patients with unexplained headaches, seizures, anxiety, and even depression showed improvement simply by switching their toothpaste or stopping the use of certain balms, revealed Padma Shri Dr Chandrashekhar Meshram, trustee of the World Federation of Neurology. "These are not allergic reactions but neurostimulation effects. We've seen cluster headaches and migraines vanish within days of stopping using particular brands," he added. A landmark case series published recently in The International Journal of Head and Face Pain also documented cluster headaches linked to toothpaste use, which resolved upon discontinuation of a particular brand. Experimental studies in zebrafish showed that even brief exposure to toothpaste triggered aggression, anxiety, and hyperactivity, suggesting potential impact on the brain. "The concern is not that these products affect everyone, but that they could be contributing to unexplained neurological symptoms in susceptible individuals," said Dr Meshram. "We need collaborative research and funding to explore safe alternatives like water or saline-based oral hygiene products." The spotlight also fell on oral health as a window to brain health. New studies linked gum disease and poor dental hygiene with higher risks of Alzheimer's, Parkinson's, and even stroke. "Regular flossing was associated with up to 22% reduction in ischemic stroke risk," noted Dr S Sen, a researcher from the US. As evidence grows, neurologists are urging both the public and policymakers to consider the hidden neuro-health impacts of seemingly benign daily products, and to explore safer, inert alternatives. THE BRAIN & BALM CONNECTION Common balms and hair oils may contain brain-stimulating chemicals Some toothpaste ingredients can trigger headaches, seizures, and anxiety A zebrafish study showed toothpaste exposure causes hyperactivity and aggression Oral health and gum disease may increase the risk of stroke and Alzheimer's Experts urge consumers to check labels and avoid the overuse of strong aromatic products
India Today
2 days ago
- India Today
Understanding frontotemporal dementia, the disease Bruce Willis is battling
When Hollywood icon Bruce Willis was diagnosed with Frontotemporal Dementia (FTD), it wasn't just another celebrity health update it was a moment of global heartbreak. For decades, Willis played characters who defied odds, cracked jokes under pressure, and carried the weight of the world with a smirk. To imagine him now struggling to find words or understand emotions feels deeply personal for many beyond the emotional impact lies a serious medical reality: FTD is one of the most common causes of early-onset dementia, yet it remains widely misunderstood, frequently misdiagnosed, and largely IS FRONTOTEMPORAL DEMENTIA?Frontotemporal Dementia is an umbrella term for a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes of the brain, regions responsible for personality, language, decision-making, behavior, and emotional regulation. Unlike Alzheimer's disease, which initially presents with memory loss, FTD often begins with changes in personality or language abilities. "While Alzheimer's typically causes memory problems, FTD starts with behavior, mood, or speech issues," says Dr. Sonia Lal Gupta, a senior neurologist. "It affects the part of the brain that makes us who we are how we interact socially, empathize, or express ourselves."Dr. Lal Gupta emphasizes that early signs can be subtle. 'Many families dismiss it as stress, depression, or a midlife crisis,' she says. 'But when someone begins behaving out of character, becomes socially inappropriate, or has trouble with language, it's time to consider a neurological evaluation.' TYPES OF FTDThere are several clinical subtypes of FTD, with overlapping symptoms:1. Behavioral variant FTD (bvFTD):Most common form; marked by changes in behavior, disinhibition, apathy, and lack of empathy.2. Primary Progressive Aphasia (PPA):Involves a gradual loss of language skills-difficulty naming objects, forming sentences, or understanding conversations.3. FTD with motor neuron disease (like ALS):In some cases, FTD co-occurs with movement disorders, including Parkinsonism or CAUSES FTD?FTD is caused by progressive nerve cell loss in the frontal and/or temporal lobes. This shrinkage leads to the loss of function in those regions. It's often sporadic, but up to 40% of cases have a genetic link, caused by mutations in specific genes like MAPT, GRN, or is not linked to lifestyle factors like smoking or poor diet, and currently, there is no cure or disease-modifying treatment. Most treatments aim to manage symptoms and improve quality of life.'Public figures sharing their diagnosis helps remove the stigma,' says Dr. Arvind Iyer, a senior neuropsychiatrist in Mumbai. 'FTD is not just 'getting old'—it's a serious condition that needs timely intervention. The more we talk about it, the earlier we can catch it, and potentially improve quality of life.'WHO DOES IT AFFECT?FTD primarily strikes people between 40 and 65 years of age, though it can appear later. This makes it especially devastating, as it often affects people at the peak of their careers and family life."FTD is under-recognized because we don't expect dementia in people in their 40s or 50s," explains Dr. Arvind Iyer, a neuropsychiatrist. "In many cases, patients are misdiagnosed with depression, bipolar disorder, or even burnout before FTD is considered."KEY SYMPTOMS TO LOOK OUT FORadvertisementEarly behavioral symptoms may include:Loss of social tact or empathyInappropriate jokes or impulsive behaviorApathy or lack of motivationObsessive or repetitive behaviorsPoor personal hygieneChanges in eating habits (e.g., overeating or preference for sweets)In language-dominant FTD:Difficulty forming words (non-fluent aphasia)Trouble understanding or remembering namesLoss of vocabularySpeaking in short, broken sentencesAs the disease progresses, symptoms may overlap with those of Alzheimer's or Parkinson's disease, making accurate diagnosis WHY EARLY RECOGNITION MATTERSCurrently, there is no single test for FTD. Diagnosis typically involves:Detailed neurological and neuropsychological evaluationsMRI or PET scans to detect brain atrophy or hypometabolismGenetic testing, especially for those with a family historyEarly diagnosis is essential to plan care, manage behavioral symptoms, and ensure the family receives support.A CAREGIVER'S REALITYCaring for someone with FTD is uniquely challenging. Patients may no longer express affection, recognize inappropriate behavior, or be able to communicate emotionally draining," shares Renu Verma, whose 68-year-old father was diagnosed with behavioral variant FTD. "He began hiding food, swearing at people, and ignoring family members. It felt like we were watching his personality melt away.""You mourn someone who's still alive," says Rajeev Sharma, caring for his older sister. "She can't follow a conversation. Her eyes are blank, but she's there. That's the hardest part."CURRENT TREATMENT OPTIONSThere is no cure for FTD, but several treatments help manage symptoms:SSRIs (antidepressants) may help with mood swings or compulsive and language therapy for those with language therapy to help with daily and support groups for families and are also exploring disease-modifying drugs, genetic therapies, and clinical trials, but progress is still in early SILVER LINING: AWARENESS IS GROWINGBruce Willis's diagnosis has cast a much-needed spotlight on FTD. It reminds us that dementia is not just an "old age" issue it can strike early, steal identity, and leave families devastated. "Public awareness is essential. FTD is often ignored in the larger dementia conversation," says Dr. Gupta. "We need more training for doctors, more resources for families, and more research funding."advertisementFrontotemporal Dementia is a thief of personality, language, and connection. But awareness, empathy, and timely care can soften the blow. Bruce Willis may have stepped away from acting, but his real-life battle is teaching us something far more powerful: the importance of recognizing the invisible battles so many families are quietly your loved one is showing unusual behavior, personality shifts, or language struggles don't wait. Talk to a neurologist. Early help can make a lifetime of difference.- EndsTrending Reel
Mint
3 days ago
- Mint
Indiqube Spaces IPO Day 3 Live: Issue booked 2.54x so far. Check GMP, review, subscription details. Apply or not?
The ₹ 700-crore initial public offering (IPO) of the firm based in Bengaluru will close today, (Friday, July 25). Indiqube Spaces IPO price band has been established at ₹ 225-237 per share. At the upper end of this range, the company's worth approaches ₹ 5,000 crore. IndiQube Spaces IPO announced on Tuesday, July 22, that it has secured over ₹ 314 crore from anchor investors, just one day before its public share-sale begins. Indiqube Spaces IPO, which opened on Wednesday, July 23, intends to raise ₹ 650 crore through a fresh issue of shares, while promoters plan to sell shares valued at ₹ 50 crore in the Offer-for-Sale (OFS). WestBridge Capital, a significant investor in the company since 2018, will not be selling any of its stake in the OFS. IndiQube Spaces aims to use the new capital, amounting to ₹ 462.6 crore, for capital expenditure on new centers, allocate ₹ 93 crore for debt repayment, and use the remaining amount for general corporate purposes. Founded in 2015, the company manages a portfolio encompassing 8.40 million square feet distributed across 115 properties in 15 cities, with a total capacity for 186,719 seats as of March 2025. This marks an increase from 74 centers and 4.94 million sq ft in March 2023. IndiQube caters to 769 clients, with 44 percent being Global Capability Centres. The company adopts an enterprise-first approach, resulting in 63 percent of its occupied space being leased by clients requiring over 300 seats. IndiQube Spaces IPO subscription status is 2.54 times on day 2, so far. The retail portion was subscribed 6.90 times, and NII portion has been booked 1.84 times, Qualified Institutional Buyers (QIBs) portion received 1.42 times bids. Employee Reserved portion has been booked 4.47 times. The company has received bids for 4,35,18,510 shares against 1,71,48,335 shares on offer, at 17:00 IST, according to data on BSE. As per brokerage SMIFS, within this sector, the Food & Beverage segment alone experienced a compound annual growth rate (CAGR) of 36.7%, with client penetration rising from 238 to 373. Additionally, related areas such as facility management, tech-driven MiQube solutions, and design-build services have enhanced revenue generation per client. The company's transition to packaged offerings and forthcoming ESG-focused "Sustainability-as-a-Service" initiatives are anticipated to further increase returns per square foot, positioning IndiQube's revenue growth to exceed industry norms through a blend of scale, prime locations, and service-oriented differentiation. 'We advise subscribing to the issue as a long-term investment, underpinned by strong industry growth patterns and fair valuations, while recognizing potential cash flow challenges in the short to medium term,' said the brokerage. IndiQube Spaces IPO grey market premium is +10. This indicates IndiQube Spaces share price was trading at a premium of ₹ 10 in the grey market, according to Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of IndiQube Spaces share price was indicated at ₹ 247 apiece, which is 4.22% higher than the IPO price of ₹ 237. Analyzing the grey market trends from the past nine sessions, the current GMP stands at ₹ 10 and indicates a downtrend. The minimum GMP recorded is ₹ 0.00, while the maximum GMP observed is ₹ 40, as stated by experts from 'Grey market premium' indicates investors' readiness to pay more than the issue price. Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
